Haemophilia APhase 3NCT02246868
An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.
A Phase 3 study testing Optivate® (Human Coagulation Factor VIII) in people with Haemophilia A, run by Bio Products Laboratory at 11 sites in 2 countries.
Trial summary
The main objectives of this study are to compare the first and second recovery assessments and recovery when a subject changed batch and to assess whether haemostasis was achieved with Optivate® when treating a bleed. The secondary objectives are to evaluate the clinical tolerance and safety of Optivate®. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Haemophilia A
- What is being tested?
- Optivate® (Human Coagulation Factor VIII)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- Not given
- Where
- 11 sitesin 2 countries
- Study dates
- Sep 2001to Aug 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Immunocompetent with severe Haemophilia A without inhibitor to FVIII, at least 12 years of age, currently receiving FVIII concentrates and have more than 150 exposures. Subjects who require elective surgergy within 6 months of starting on OPTIVATE® are permitted to be included in this study providing that the surgery could be performed using OPTIVATE® as FVIII cover.
Who cannot join
- -
Trial locations and contacts
11 sites in 2 countries.
11 sites in 2 countries
Poland6 sites
Klinika Haematologii, Akademia Medyczna w Bialymstokiu, ul.
Bialystok
Klinika Haematologii, Akademia Medyczna w Gdansku, u.
Gdansk
Klinika Haematologii, Akademia Medyczna w Lodzi, ul.
Lodz
Klinika Haematologii, Akademia Medyczna w Lublinie, ul.
Lublin
Klinika Haematologii, Akademia Medyczna w Poznaniu, ul.
Poznan
Klinika Haematologii, Akademia Medyczna w Wroclawiu, ul.
Wroclaw
United Kingdom5 sites
Haemophilia Centre, Addenbrooke's Hospital, Hills Road
Cambridge, CB2 2QQ
Haemophilia Centre, University Department of Haemophilia Manchester Royal Infirmary
Manchester, M13 9WL
Haemophilia Centre, University Hospital, Queen's Medical Centre, Clifton Boulevard
Nottingham, NG7 2UH
Sheffield Haemophilia & Thrombosis Centre, Royal Hallamshire Hospital, Glossop Road
Sheffield, S10 2JF
Haemophilia Centre, Southampton General Hospital, Tremona Road
Southampton, SO16 6YD
About this study
The main objectives of this study are to compare the first and second recovery assessments and recovery when a subject changed batch and to assess whether haemostasis was achieved with Optivate® when treating a bleed. The secondary objectives are to evaluate the clinical tolerance and safety of Optivate®.
- Conditions
- Haemophilia A
- Being tested
- Optivate® (Human Coagulation Factor VIII)
- Medical subject headings
- Hemophilia A
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Optivate® (Human Coagulation Factor VIII)Biological
| Study group | Role | What they receive |
|---|---|---|
| Optivate® | Experimental | Optivate® (Human Coagulation Factor VIII) Receives: Biological: Optivate® (Human Coagulation Factor VIII) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incremental Recovery
Measured: Comparison of Baseline with 3 months post-baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2014 (estimated)
- Study startSep 2001
- Primary completionAug 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Haemophilia AStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
Sponsor and investigators
- Lead sponsor
- Bio Products Laboratory
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02246868
- Sponsor's protocol ID
- 8VWFSE
- Status last verified
- Feb 2018
- First submitted
- 2 Sep 2014
- Last updated
- 15 Feb 2018
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.
- ClinicalTrials.gov ID
- NCT02246868
- Acronym / sponsor ID
- 8VWFSE
- Conditions
- Haemophilia A
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- Bio Products LaboratoryUniversity, hospital or other
- Study start
- Sep 2001
- Primary completion
- Aug 2004 (actual)
- First posted
- 23 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objectives of this study are to compare the first and second recovery assessments and recovery when a subject changed batch and to assess whether haemostasis was achieved with Optivate® when treating a bleed. The secondary objectives are to evaluate the clinical tolerance and safety of Optivate®.
Study design
- Primary purpose
- Treatment
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Optivate® | Experimental | Biological: Optivate® (Human Coagulation Factor VIII)Optivate® (Human Coagulation Factor VIII) |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Immunocompetent with severe Haemophilia A without inhibitor to FVIII, at least 12 years of age, currently receiving FVIII concentrates and have more than 150 exposures. Subjects who require elective surgergy within 6 months of starting on OPTIVATE® are permitted to be included in this study providing that the surgery could be performed using OPTIVATE® as FVIII cover.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Optivate® (Human Coagulation Factor VIII) | Biological | Optivate® |
Primary outcome
Incremental Recovery
Time frame: Comparison of Baseline with 3 months post-baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2018.
- Related InfoLink provided by the sponsor.
Related trials for Haemophilia A
Not yet recruiting
Safety of Intraosseous Anaesthesia in Children With Haemophilia
Haemophilia A, Haemophilia B
RecruitingPhase 3
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
Haemophilia A
Active, not recruitingPhase 3
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
Haemophilia A (Moderate or Severe)
Enrolling by invitationObservational study
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
Haemophilia B
Enrolling by invitationObservational study
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
Haemophilia A
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
11 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Optivate® (Human Coagulation Factor VIII) in people with Haemophilia A, run by Bio Products Laboratory at 11 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in Poland, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incremental Recovery (time frame: Comparison of Baseline with 3 months post-baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2018; AzTrials last refreshed its copy on 6 Nov 2026.